title: An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.
abstract: BACKGROUND
  Tegaserod has been shown to be an effective therapy for the multiple symptoms of irritable bowel syndrome (IBS) in Western populations. However, little information is available regarding the use of tegaserod in the Asia-Pacific population.
  
  
  OBJECTIVE
  To evaluate the efficacy, safety, and tolerability of tegaserod versus placebo in patients with IBS from the Asia-Pacific region.
  
  
  METHODS
  A total of 520 patients from the Asia-Pacific region with IBS, excluding those with diarrhoea predominant IBS.
  
  
  METHODS
  Patients were randomised to receive either tegaserod 6 mg twice daily (n=259) or placebo (n=261) for a 12 week treatment period. The primary efficacy variable (over weeks 1-4) was the response to the question: "Over the past week do you consider that you have had satisfactory relief from your IBS symptoms?" Secondary efficacy variables assessed overall satisfactory relief over 12 weeks and individual symptoms of IBS.
  
  
  RESULTS
  The mean proportion of patients with overall satisfactory relief was greater in the tegaserod group than in the placebo group over weeks 1-4 (56% v 35%, respectively; p<0.0001) and weeks 1-12 (62% v 44%, respectively; p<0.0001). A clinically relevant effect was observed as early as week 1 and was maintained throughout the treatment period. Reductions in the number of days with at least moderate abdominal pain/discomfort, bloating, no bowel movements, and hard/lumpy stools were greater in the tegaserod group compared with the placebo group. Headache was the most commonly reported adverse event (12.0% tegaserod v 11.1% placebo). Diarrhoea led to discontinuation in 2.3% of tegaserod patients. Serious adverse events were infrequent (1.5% tegaserod v 3.4% placebo).
  
  
  CONCLUSIONS
  Tegaserod 6 mg twice daily is an effective, safe, and well tolerated treatment for patients in the Asia-Pacific region suffering from IBS and whose main bowel symptom is not diarrhoea.
authors.affiliation: Royal North Shore Hospital, Sydney, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Kellow
authors.forename: O Y
authors.initials: OY
authors.lastname: Lee
authors.forename: F Y
authors.initials: FY
authors.lastname: Chang
authors.forename: S
authors.initials: S
authors.lastname: Thongsawat
authors.forename: M Z
authors.initials: MZ
authors.lastname: Mazlam
authors.forename: H
authors.initials: H
authors.lastname: Yuen
authors.forename: K A
authors.initials: KA
authors.lastname: Gwee
authors.forename: Y T
authors.initials: YT
authors.lastname: Bak
authors.forename: J
authors.initials: J
authors.lastname: Jones
authors.forename: A
authors.initials: A
authors.lastname: Wagner
mesh_terms: D000328:Adult; D003109:Colonic Diseases, Functional / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003967:Diarrhea / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D005765:Gastrointestinal Agents; D007211:Indoles; C105050:tegaserod